# ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

- Link: https://www.thailand-business-news.com/pr-news/arkbios-rsv-antiviral-drug-ziresovir-receives-fda-approval-for-phase-ii-clinical-trial
- Published: 2026-08-14T17:18:00+07:00
- Author: PR Newswire

|   |

SHANGHAI, Aug. 14, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. ("
ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has approved
ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected
infant patients, including the ones in pediatric intensive care unit (PICU).

**Severe RSV Infection: An Urgent Unmet Need in PICU**

RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants
and young children globally, causing approximately 33 million LRTI cases, 3.6 million
hospitalizations, and more than 100,000 deaths annually. Severely ill RSV infected
infants often require admission to the PICU for intensive care such as respiratory
support, with rapid disease progression, high risk and a heavy medical burden. There
is currently no approved RSV-specific antiviral therapy worldwide; clinical management
remains limited to symptomatic and supportive care, such as oxygenation, leaving
an urgent unmet need for effective antiviral treatment in hospitalized RSV infected
patients with severe diseases.

**Ziresovir Advances to Treat Severely Infected Infant Patients**

Ziresovir is the first direct RSV antiviral drug to successfully complete a phase
III clinical trial with positive results. The clinical study in 1-24 months age 
patients conducted in China demonstrated that ziresovir can significantly reduce
viral load, accelerate the resolution of respiratory symptoms, and significantly
lower the risk of recurrent wheezing and asthma over 24-month follow-up period, 
with a favorable safety profile. Key findings from the clinical study have been 
published in _The New England Journal of Medicine_ and _The Lancet Child & Adolescent
Health_. In 2025, ziresovir was included as the only therapeutic drug in the WHO’s
Paediatric Drug Optimization for Respiratory Syncytial Virus publication. The newly
approved phase II clinical trial marks the extension of ziresovir’s clinical development
into the most critically ill RSV patients, representing a key milestone in the clinical
development of ziresovir globally.

**FDA Approved Phase II Clinical Trial**

The approved multicenter, randomized, double-blind, placebo-controlled phase II 
clinical trial will focus on severely ill RSV infected infants requiring hospitalization
in PICU, one of the most critical RSV patient populations with the most urgent clinical
treatment needs. This clinical trial is designed to evaluate clinical efficacy of
ziresovir, especially the length of oxygen treatment and sustained recovery time,
providing the clinical basis for the future registrational trials.

**About ArkBio**

ArkBio is a commercial-stage biotechnology company focused on the discovery and 
development of innovative therapeutics for respiratory/lung and pediatric diseases.
Founded in 2014, the company has established proprietary technology platforms and
a differentiated R&D pipeline through internal innovation and strategic collaborations.

Key pipeline assets include: ziresovir (AK0529), the first direct-acting antiviral
for RSV with positive phase 3 results; AK3280, a potentially best-in-class anti-
fibrotic agent with positive phase 2 results in idiopathic pulmonary fibrosis, currently
in phase 3 registrational trials; AK0901, approved and commercialized in China for
ADHD treatment. The company also has multiple first-in-class or best-in-class innovative
drug candidates in clinical or preclinical development.

ArkBio has established strategic partnerships with multinational pharmaceutical 
companies including Roche and Genentech, leading academic institutions including
The Scripps Research Institute and the Institute of Microbiology of the Chinese 
Academy of Sciences, Qilu Pharmaceutical, as well as other domestic and international
biotech companies and CROs.

For more information, please visit: [www.arkbiosciences.com](https://www.arkbiosciences.com/)

Investor Inquiries: [IR@arkbiosciences.com](https://www.thailand-business-news.com/pr-news/IR@arkbiosciences.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial ](http://www.prnasia.com/story/archive/5026507_AE26507_0?rand=184833)
